Government of Canada / Gouvernement du Canada
Symbol of the Government of Canada

Search

Food and Drug Regulations (C.R.C., c. 870)

Regulations are current to 2020-11-02 and last amended on 2020-09-28. Previous Versions

PART JRestricted Drugs (continued)

Licensed Dealers (continued)

Sale of Restricted Drugs (continued)

Marginal note:Sale to Minister

 A licensed dealer may sell or provide a restricted drug to the Minister.

  • SOR/2019-171, s. 22

Marginal note:Provision for identification or analysis

  •  (1) Despite anything in this Part, a person may, for the purpose of identification or analysis of a restricted drug, provide or deliver it to

    • (a) a practitioner of medicine; or

    • (b) an agent or mandatary of a practitioner of medicine, if the agent or mandatary has been exempted under section 56 of the Act with respect to the possession of that restricted drug for that purpose.

  • Marginal note:Agent or mandatary of practitioner of medicine

    (2) An agent or mandatary of a practitioner of medicine who receives the restricted drug must immediately provide or deliver it to

    • (a) the practitioner; or

    • (b) the Minister.

  • Marginal note:Practitioner of medicine

    (3) A practitioner of medicine who receives the restricted drug must immediately provide or deliver it

    • (a) for the purpose of its identification or analysis, to a person exempted under section 56 of the Act with respect to the possession of that restricted drug for that purpose; or

    • (b) to the Minister.

  • SOR/2019-171, s. 22

Packaging, Labelling and Transportation

Marginal note:Packaging — sale and provision

  •  (1) A licensed dealer that sells or provides a restricted drug must securely package it in its immediate container, which must be sealed in such a manner that the container cannot be opened without breaking the seal.

  • Marginal note:Packaging — transport and export

    (2) A licensed dealer that transports or exports a restricted drug must ensure that its package is sealed in such a manner that the package cannot be opened without breaking the seal.

  • Marginal note:Exception

    (3) Subsection (1) does not apply to a test kit that contains a restricted drug and that has a registration number.

  • SOR/2019-171, s. 22

Marginal note:Labelling

  •  (1) A licensed dealer that sells or provides a restricted drug must ensure that its package is labelled so that its inner and outer labels show

    • (a) the proper name or, if there is no proper name, the name of the drug;

    • (b) the net contents of the package;

    • (c) the unit strength of the drug and the number of units per package, if applicable;

    • (d) the lot number of the drug;

    • (e) the expression “Restricted Drug”; and

    • (f) the name and municipal address of the manufacturer or assembler of the drug.

  • Marginal note:Exception

    (2) Subsection (1) does not apply to a test kit that contains a restricted drug and that has a registration number.

  • Marginal note:Non-application

    (3) The labelling requirements set out in section C.01.004 do not apply to a restricted drug.

  • SOR/2019-171, s. 22

Marginal note:Transport

 A licensed dealer must, in taking delivery of a restricted drug that they have imported or in making delivery of a restricted drug,

  • (a) take any measures that are necessary to ensure the security of the drug while it is being transported;

  • (b) use a method of transportation that permits an accurate record to be kept of all handling of the drug as well as of the signatures of every person handling it until it is delivered to the consignee;

  • (c) in the case of an imported drug, transport it directly to the site specified in their licence after it is released under the Customs Act; and

  • (d) in the case of a drug to be exported, transport it directly from the site specified in their licence to the customs office where it will be exported.

  • SOR/2019-171, s. 22

Thefts, Losses and Suspicious Transactions

Marginal note:Protective measures — licences and permits

 A licensed dealer must take any measures that are necessary to ensure the security of any licence or permit in their possession.

  • SOR/2019-171, s. 22

Marginal note:Protective measures — restricted drugs

 The following persons must take any measures that are necessary to ensure the security of any restricted drugs in their possession:

  • (a) a licensed dealer;

  • (b) an institution;

  • (c) a qualified investigator who possesses the restricted drug for the purpose of clinical testing or laboratory research in an institution; and

  • (d) a person exempted under section 56 of the Act with respect to the possession of the restricted drug.

  • SOR/2019-171, s. 22

Marginal note:Theft or loss — licences and permits

 A licensed dealer that becomes aware of a theft or loss of their licence or permit must provide a written report to the Minister within 72 hours after becoming aware of it.

  • SOR/2019-171, s. 22

Marginal note:Theft or loss — restricted drugs

  •  (1) Subject to subsection (2), any person referred to in section J.01.066 who becomes aware of a theft or loss of a restricted drug must

    • (a) provide a written report to a member of a police force within 24 hours after becoming aware of the theft or loss; and

    • (b) provide a written report to the Minister within 72 hours after becoming aware of the theft or loss and include a confirmation that the report required under paragraph (a) has been provided.

  • Marginal note:Explainable loss — licensed dealer

    (2) Subsection (1) does not apply to a licensed dealer that becomes aware of a loss of a restricted drug that can be explained on the basis of normally accepted business activities.

  • SOR/2019-171, s. 22

Marginal note:Suspicious transaction

  •  (1) A licensed dealer must provide a written report containing the following information to the Minister within 72 hours after becoming aware of a transaction occurring in the course of their activities that they have reasonable grounds to suspect may be related to the diversion of a restricted drug to an illicit market or use:

    • (a) their name, municipal address, telephone number and, if the licensed dealer is a corporation, the position held by the individual making the report;

    • (b) the name and municipal address of the other party to the transaction;

    • (c) details of the transaction, including its date and time, its type, the name and quantity of the restricted drug and, in the case of a product or compound, the quantity of every restricted drug that it contains;

    • (d) in the case of a product that contains the restricted drug, other than a test kit, the drug identification number that is assigned to the product under section C.01.014.2, if any; and

    • (e) a detailed description of the reasons for those suspicions.

  • Marginal note:Good faith

    (2) No civil proceedings lie against a licensed dealer for having provided the report in good faith.

  • Marginal note:Non-disclosure

    (3) A licensed dealer must not disclose that they have provided the report or disclose details of it, with the intent to prejudice a criminal investigation, whether or not a criminal investigation has begun.

  • SOR/2019-171, s. 22
 
Date modified: